Tag Archives: Ligand Pharma

The EVP,Finance & Strategy and CFO of Ligand Pharma (NASDAQ: LGND) is Buying Shares

Yesterday, the EVP,Finance & Strategy and CFO of Ligand Pharma (LGND – Research Report), Matthew Korenberg, bought shares of LGND for $43.09K. In addition to Matthew Korenberg, 4 other LGND executives reported Buy trades in the last month. Following this

The CEO of Ligand Pharma (NASDAQ: LGND) is Buying Shares

Yesterday, the CEO of Ligand Pharma (LGND – Research Report), John L. Higgins, bought shares of LGND for $176.6K. This recent transaction increases John L. Higgins’ holding in the company by 1.28% to a total of $13.43 million. See today’s

The President & COO of Ligand Pharma is Exercising Options

Yesterday it was reported that the President & COO of Ligand Pharma (LGND – Research Report), Matthew W. Foehr, exercised options to buy 1,004 LGND shares at $21.92 a share, for a total transaction value of $22.01K. In addition to

Ligand Pharma (LGND) Gets a Buy Rating from H.C. Wainwright

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $214. The company’s shares closed yesterday at $123.86, close to its 52-week low of

A Director at Ligand Pharma (NASDAQ: LGND) is Buying Shares

Today, a Director at Ligand Pharma (LGND – Research Report), Jason Aryeh, bought shares of LGND for $22.73K. This is Aryeh’s first Buy trade following 14 Sell transactions. In addition to Jason Aryeh, 2 other LGND executives reported Buy trades

H.C. Wainwright Thinks Ligand Pharma’s Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $254. The company’s shares closed yesterday at $113.35, close to its 52-week low of $98.56. Pantginis noted: